Key resistance, page-7

Yes the wording in the Annual Report

"The response provided by Tissue Therapies to the EMA provides detailed answers to the review questions and is expected to result in a favourable EMA opinion during the second half of 2014, as previously announced (ASX: TIS Appendix 4D and CE Mark Update, 26 February 2014)."

is so positive in wording that it would positively impact SP. I still intend to wait for approval or informal confirmation is I buy another big chunk, but I may not be getting much bang for my buck by then but it is the real risk ie not getting CE mark, no matter how in the bag it sounds. The two outcomes you mention GL maybe sub 10c or $1 up (bearing in mind sometimes do not not jump there immed on confirmation when something is expected).

With the number of successful class actions against public companies and directors there must be some basis for there sales estimates released in March which show the company moving to tens and hundreds of millions quite rapidly or they have their assets in their wives names